Epstein-Barr virus (EBV) contributes to the development of several human cancers including the endemic form of Burkitt's lymphoma (BL). In culture, EBV induces the continuous proliferation of primary B cells as lymphoblastoid cell lines (LCLs) and if EBV-negative BL-derived cells are infected with EBV, latency-associated viral factors confer resistance to various inducers of apoptosis. Nuclear proteins EBNA3A and EBNA3C (but not EBNA3B) are necessary to establish LCLs and their expression may be involved in the resistance of BL cells to cytotoxic agents. We have therefore created recombinant EBVs from which each of the EBNA3 genes has been independently deleted, and revertant viruses in which the genes have been re-introduced into the viral genome. Infection of EBVnegative BL cells with this panel of EBVs and challenge with various cytotoxic drugs showed that EBNA3A and EBNA3C cooperate as the main determinants of both drug resistance and the downregulation of the proapoptotic Bcl-2-family member Bcl-2-interacting mediator of cell death (Bim). The regulation of Bim is predominantly at the level of RNA, with little evidence of post-translational Bim stabilization by EBV. In the absence of Bim, EBNA3A and EBNA3C appear to provide no survival advantage. The level of Bim is a critical regulator of B cell survival and reduced expression is a major determinant of lymphoproliferative disease in mice and humans; moreover, Bim is uniquely important in the pathogenesis of BL. By targeting this tumour-suppressor for repression, EBV significantly increases the likelihood of B lymphomagenesis in general, and BL in particular. Our results may also explain the selection pressure that gives rise to a subset of BL that retain expression of the EBNA3 proteins.
Introduction
In vitro, Epstein-Barr virus (EBV) can very efficiently induce the continuous proliferation of primary human B cells. The resulting 'immortalized' lymphoblastoid cell lines (LCLs) carry the viral genome as extrachromosomal episomes and express only nine EBV 'latency' proteins. Six nuclear antigens (EBNA1, 2, 3A, 3B, 3C and LP) and three membrane-associated proteins (LMP1, LMP2a and 2b) plus several RNA species constitute what is known as the latency-III pattern of EBV gene expression found in LCLs (reviewed in Bornkamm and Hammerschmidt, 2001) .
Despite asymptomatically infecting most of the human population, EBV is linked to the aetiology of at least three important B cell cancers: endemic Burkitt's lymphoma (eBL), post-transplant lymphoproliferative disease (PTLD) and 30-50% of Hodgkin's lymphoma. Each of these tumours has a distinct cellular phenotype (or range of phenotypes) and generally expresses a characteristic pattern of EBV latency proteins (Young and Rickinson, 2004 ). The precise role played by EBV in the development of these B-lymphomas is still not completely understood-this is particularly the case with eBL (O'Nions and Allday, 2004) .
The EBV latency-associated proteins, EBNA3A, EBNA3B and EBNA3C, are considered to comprise a family, which probably arose by a series of gene duplication events since they share limited but significant amino-acid sequence homology, have the same gene structure (that is, a short 5 0 coding exon and a long 3 0 coding exon) and are arranged in tandem in the EBV genome (Bornkamm and Hammerschmidt, 2001 ). Although they are related and albeit they share certain features, there is nothing to suggest that the EBNA3 proteins have extensively redundant functions (reviewed in Bornkamm and Hammerschmidt, 2001; O'Nions and Allday, 2004) . Genetic studies using recombinant viruses have shown that EBNA3A and EBNA3C are essential for the efficient immortalization of B cells, whereas EBNA3B is dispensable (Tomkinson et al., 1993) . All the EBNA3 proteins associate with the cellular DNA-binding factor RBP-JK/CBF1. This protein also binds to, and targets to DNA, the EBV transactivator EBNA2. The EBNA3s bind to the same site on RBP-JK/CBF1 as EBNA2 and can all inhibit EBNA2-mediated activation of the latency promoter Cp (Zimber-Strobl and Strobl, 2001 ; our unpublished data). Since Cp is generally the promoter for initiation of all EBNA mRNA in established LCLs, the EBNA3s probably contribute to a negative autoregulatory loop. All three EBNA3s are robust repressors of transcription when targeted to DNA (Bain et al., 1996; Bourillot et al., 1998; Cludts and Farrell, 1998; Hickabottom et al., 2002; our unpublished data) . Consistent with this, EBNA3A and EBNA3C interact with histone deacetylases and bind directly to the cellular co-repressor of transcription CtBP (Radkov et al., 1999; Touitou et al., 2001; Hickabottom et al., 2002; Knight et al., 2003) . CtBP-containing complexes can coordinate biochemical and enzymatic events that convert transcriptionally active chromatin into a repressive or silent state (Chinnadurai, 2002; Shi et al., 2003) . EBNA3A and EBNA3C also cooperate with mutant Ras in the immortalization and transformation of primary rodent fibroblasts (Touitou et al., 2001; Hickabottom et al., 2002) .
Recently, we and others discovered that in BL cells latent EBV provides significant protection from programmed cell death induced by a variety of cytotoxic agents (Kelly et al., 2005 (Kelly et al., , 2006 Leao et al., 2007) . Analysis of EBV latent gene expression patterns in various EBV-positive BL-derived cell lines suggested that the EBNA3 family might play an important role in this survival phenotype. Correlation between survival and EBV-mediated repression of the BH3-only, Bcl-2-family member Bim (Bcl-2-interacting mediator of cell death) was also observed (Leao et al., 2007) .
To evaluate the contribution made by each of the EBNA3 proteins to B cell survival, we constructed a series of recombinant EBVs using a bacterial artificial chromosome (BAC) system (Delecluse et al., 1998) . Mutant EBVs were produced that include deletions of the individual EBNA3 genes and, importantly, viruses in which the deleted EBNA3 gene was restored to the viral genome (revertants) were also created. These viruses were used to infect EBV-negative BL cells. Analysis of the EBNA3-knockout (KO) series of BL31 cell lines after exposure to three different cytotoxic drugs revealed that survival was dependent on both EBNA3A and EBNA3C and correlated with a significant reduction in the expression of all three major isoforms of Bim, Bim EL (extra long), Bim L (long) and Bim S (short). The data suggest a model for how EBV might contribute to the pathogenesis of BL.
Results

Validation of recombinant viruses in BL31 cells
The construction, screening and validation of EBVBACs are described in Supplementary Information. Infectious virus was produced from EBNA3-deletion and -revertant BACs maintained in 293 cells (Figures 1a  and b) . Several 293 producer cell clones were generated for each KO and revertant BAC. Virus-containing supernatants from these 293 cells, and from producer cells containing the wild-type (parental) p2089 BAC (clone F2), were used to infect the EBV-negative BL-derived cell line BL31. Once stable lines were established, cells were harvested for western-blot analysis with antibodies directed against the EBV latencyassociated proteins. Representative examples are shown in Figure 1c . In all the lines examined, the only proteins completely absent were those expected from the specific deletions created in the KO viruses.
Multiple western blots were performed on extracts from the BL31 series of cell lines and the only consistent change in EBV latent protein expression (other than the absence of the targeted gene product) was an increase in the amount of EBNA2 detected when either EBNA3A or EBNA3C was deleted. One other variation worth noting was the altered pattern of EBNA-LP expressed in three EBNA3C-KO lines (EBNA3C KO (2), (3) and (4)). These lines were infected with the 3CKO þ BamW virus that has two additional W repeat elements (see Supplementary Information) so we conclude that this alters the amount and size of EBNA-LP synthesized. These, and other variations recorded (for example, a reduction in several proteins in BL31-EBNA3B KO (2) or the reduction in LMP1 in BL31-EBNA3C KOs (1-3)), did not correlate with the Bim or survival phenotypes described below.
Although it has been reported that EBNA3C might be necessary to activate LMP1 expression efficiently (Rosendorff et al., 2004; Jimenez-Ramirez et al., 2006) , no consistent reduction in LMP1 was detected when EBNA3C was absent from these cells (for example, EBNA3C KO (4) in Figure 1c and also 3CKO (2) in BL2 cells, shown in Figure 5b , have as much or more LMP1 than the revertant carrying lines). Furthermore, the expression levels of two anti-apoptotic proteins (Bcl-2 and A20)-that can be upregulated by LMP1 in BL cells (Henderson et al., 1991; Laherty et al., 1992) remained relatively constant irrespective of whether EBNA3A, 3B or 3C were expressed (see, for example, EBNA3C KO (1) in Figure 1d ).
The integrity of EBV-BAC DNA recovered from converted BL31 cell lines was also assessed (see Supplementary Information).
EBNA3A and EBNA3C cooperate to rescue BL cells from nocodazole-induced death When multiple cell lines established with each of the recombinant viruses had been validated by western blotting, cell samples were treated with nocodazole for 72 h. We showed previously that after this length of time all BL31 cells were dead as a result of caspase-dependent programmed cell death (Leao et al., 2007) . Here, counting viable cells confirmed this and also showed that the B95.8 wild-type virus protects up to 70% of the BL31 cells from death (Figures 2a and b) . The EBNA2-KO-infected cells, all the revertant and EBNA3B-KO cells behaved in an essentially similar manner to the wild-type EBV line, that is most cells survived. In contrast, after similar treatment, only 20% or fewer of the EBNA3A-and EBNA3C-KO cells remained viable. Since in each case the unaffected genes cannot compensate for the deleted family member, we conclude that EBNA3A and EBNA3C must cooperate to protect the cells from nocodazole-induced death. The survival of up to 20% of the cells infected with these deletion mutants suggests that EBV factors other than EBNAs 3A and 3C may make a modest contribution to B-cell survival. Western blotting for the caspase-substrate poly (ADPribose) polymerase (PARP) confirmed that cell death was associated with caspase activity, and therefore apoptosis, and that latent EBV inhibited this only when both EBNA3A and EBNA3C were expressed (Figure 2c ).
EBNA3A and EBNA3C cooperate to rescue BL cells from apoptosis induced by other cytotoxic drugs Similar experiments to those in which nocodazole was the inducer of cell death were performed using other drugs known to be cytotoxic to BL cells. Cisplatin (a DNA cross-linking agent) and roscovitine (a cyclin-dependent kinase inhibitor) both induce apoptosis in B cells, and EBV significantly reduces sensitivity to both (Wade and Allday, 2000; Alvi et al., 2005 and our unpublished data). As with the nocodazole experiments, deletion of EBNA3A or EBNA3C substantially reduced the percentage of cells survivingindicating that the rescue phenotype is not only restricted to drugs that activate the mitotic spindle checkpoint (Figure 3 ). The recombinant viruses used in the study. The EBNA2-knockout (KO) virus (*) is described in Kelly et al. (2005) . (c) BL31 cells converted by infection with recombinant EBVs express the expected EBV latency-associated proteins. Protein extracts were prepared from BL31 cells infected with wild-type EBV (WT), EBNA3A-, EBNA3B-and EBNA3C-KO and revertant (Rev) viruses, and from parental BL31 cells and a lymphoblastoid cell line (LCL). Proteins were resolved by SDS-PAGE and western immunoblotted with antibodies against EBV latent proteins and actin (a control for equal loading). (d) Protein extracts from BL31 cells and BL31 cells infected with KO and revertant viruses were also subjected to western-blot analysis probing for expression of the anti-apoptotic factors (and targets of LMP-1), A20 and Bcl-2; g-tubulin was used as a loading control. EBNA3A and EBNA3C are both required for repression of Bim expression It was shown previously that latent infection of BL cells with EBV results in a significant reduction in the expression of the proapoptotic Bcl-2-family member, Bim (Clybouw et al., 2005; Leao et al., 2007) . Moreover, this downregulation appears not to require expression of EBNA2 or the LMP proteins (Leao et al., 2007) . Therefore to determine whether any of the EBNA3 proteins are necessary for the repression of Bim expression in BL cells, western blots using a Bim-specific polyclonal antibody were performed on the BL31 cells infected with each of the EBNA3 KO and revertant viruses. For comparison, extracts from BL31 cells carrying wild-type or an EBNA2-KO virus and primary B cells either stimulated with mitogens or growth transformed with EBV (LCL-BF) were also analysed ( Figure 4a shows representative examples). BL31 cells express a high level of the largest isoform of Bim (Bim EL ) and detectable levels of Bim L and Bim S (see also Figures 4b and 5a) . Expression of all three isoforms is reduced by latent infection with the wild-type EBV and the EBNA2-KO virus. Primary B cells stimulated by the mitogens CD40-ligand and IL4 express a very similar pattern of Bim to BL31, whereas the EBV-positive LCL expresses a low level of Bim EL , while Bim L and Bim S are undetectable. These data are consistent with reports that all mature B cells express significant amounts of Bim Figure 4 EBNA3A and EBNA3C cooperate to repress the expression of Bcl-2-interacting mediator of cell death (Bim). (a) Protein extracts from primary B cells stimulated with mitogens (CD40L þ IL4), an LCL (LCL-BF), uninfected BL31 cells or EBV-infected BL31 cells were separated by SDS-PAGE (12.5%) and western immunoblotted using an antibody against Bim. The three Bim isoforms, extra long (EL), long (L) and short (S), are indicated. Wild-type (WT) EBV inhibits Bim expression in the LCL and WTinfected BL31. Bim expression is also repressed by infection with EBNA2-knockout (E2KO), EBNA3B KO and all the revertant (Rev) viruses, but not by infection with the EBNA3A or EBNA3C-KO viruses (3AKO and 3CKO). (b) Blocking phosphorylation of extracellular signal regulated kinase (ERK) 1 and 2 does not lead to a significant increase in Bim levels. BL31, wild-type EBV-infected BL31 and BL31 infected with an EBNA2-KO virus (E2KO), were treated with the MEK inhibitor, U0126 (20 mM) and samples taken from treated and untreated (Un) cell populations at the times indicated. Protein extracts were prepared, separated by SDS-PAGE (12.5%) and western immunoblotted using antibodies against Bim, ERK1/2, phospho-ERK1/2 and g-tubulin. (For Bim, a long exposure (LE) and short exposure (SE) are shown). (c) ERK phosphorylation in proliferating normal primary B cells and an LCL. Protein extracts used in (a), separated by SDS-PAGE (12.5%) and western immunoblotted using antibodies against Bim, ERK1/2, phospho-ERK1/2 and g-tubulin. (d) Latent EBV downregulates Bim EL mRNA. Expression of Bim EL mRNA was measured using quantitative RT-PCR. Levels of Bim EL mRNA in EBV-negative BL31 cells were compared to those in BL31 cells converted with KO and revertant viruses, and levels in normal B cells stimulated with CD40-ligand and IL4 were compared to those in LCLs. Bim EL mRNA levels in these cells were normalized to the mRNA of GAPDH. For the BL31 lines, the mean and standard deviation of three experiments (each using triplicate RNA samples) is shown. For the comparison of primary B cells with the LCLs, only a single triplicate experiment is shown. O'Reilly et al., 2000; Strasser, 2005) and show thateven in the setting of 'normal' B cells-latent EBV inhibits Bim expression. Comparison of the EBNA3-KO BL31 cells showed that deletion of EBNA3B had no effect on Bim expression-it remains very low, as it does in all the revertant lines. In contrast, deletion of either EBNA3A or EBNA3C relieved the EBV-mediated repression, indicating that these two oncoproteins are both necessary to reduce the expression of all three isoforms of Bim.
EBNA3A and
Repression involves downregulation of Bim mRNA, but not phosphorylation of Bim protein It has been suggested that EBV infection may lead to post-translational modulation of Bim expression (Clybouw et al., 2005) . It is thought that latent EBV induces phosphorylation of extracellular signal regulated kinase (ERK) and that phospho-ERK phosphorylates Bim; since phosphorylated Bim is then ubiquitinylated, this cascade of modifications leads to rapid degradation of Bim by the proteasome system. To determine whether inhibition of ERK phosphorylation leads to a restoration of Bim levels in the presence of latent EBV, BL31 and BL31 infected with wild-type EBV or the EBNA2-KO virus were all treated with the MEK inhibitor U0126 that blocks phosphorylation of ERK (Ley et al., 2003) . The results shown in Figure 4b confirm that EBV (and EBV that does not express EBNA2) constitutively activate ERK, since ERK was present but not phosphorylated in BL31, whereas the phosphorylated forms were clearly present in the EBV-infected cells. However, although in the cells carrying wild-type EBV there is a very slight increase in Bim after treatment with the inhibitor U0126, the increase cannot account for the difference between infected and uninfected cells produced by EBV latent gene expression (Figure 4b , compare tracks 1-5 with tracks 9 and 10). Also, even this very modest increase was not produced in a line infected with the EBNA2-KO virus (which in the survival and Bim assays behaves in essentially the same way as lines carrying wild-type EBV). This indicated that in these BL cells a failure to phosphorylate Bim does not necessarily lead to significant stabilization (and accumulation) of any Bim isoforms and that the low level of protein found in EBV-positive cells is therefore unlikely to be the result of constitutively active ERK phosphorylating Bim. Consistent with our results in BL cells that suggest EBV does not regulate Bim posttranslationally, we found that ERK was constitutively phosphorylated to a similar extent in primary B cells stimulated by mitogens as in similar cells driven by EBV to become an LCL (Figure 4c) (Figure 4d ). The results consistently showed a very good correlation between reduced Bim EL mRNA and the amount of protein detected in western blots. We conclude that EBNA3A and EBNA3C cooperate to suppress the level of Bim mRNA.
In the absence of Bim, EBNA3A and EBNA3C provide no survival advantage To determine whether Bim is necessary for EBNA3A/ 3C-mediated survival, use was made of a second BLderived cell line, BL2. These cells differ from BL31 in two important respects: they do not express detectable amounts of Bim protein or the corresponding RNA and they have two wild-type alleles for the tumour-suppressor p53 (Figure 5a , our unpublished data, Table 1 and Lindstrom et al., 2001) . This is in contrast to BL31 that-like most BL-derived cell lines-expresses only mutant p53 and consequently its response to cytotoxic agents is independent of p53-mediated pathways (see Table 1 ).
The EBV-infected (BimÀve, p53 þ ve) BL2 lines were established and validated for EBV gene expression and episomal integrity following essentially the same protocol as the one used in the creation of the BL31 lines. Figure 5b shows examples of EBV protein expression and, as in BL31, only the deleted genes were not expressed. Consistent with the hypothesis that downregulation of Bim is a major determinant of EBNA3A/ EBNA3C-mediated rescue from nocodazole-induced cell death, failure to express either EBNA3A or EBNA3C in BL2 made no significant difference to the cells' responses. After exposure to nocodazole, BL2 cells-irrespective of whether they express EBV latency proteins-fail to survive and 65-95% were dead via a caspase-associated pathway after 72 h (Figures 5c and  d) . Similar results were obtained when cisplatin or roscovitine were used (data not shown). In the absence of Bim, EBNA3A and EBNA3C do not protect BL cells from various cytotoxic stimuli. We assume that these cells die because the activated wild-type p53 induces expression of its proapoptotic target, the BH3-only protein Noxa (Figure 5e ). This is consistent with our previous observations that EBV does not impair p53-mediated apoptotic responses in LCLs (Bim þ ve, p53 þ ve) and confirms that EBNA3A and EBNA3C do not interfere with the p53/Noxa-induced pathway to apoptosis in B cells (Allday et al., 1995; O'Nions and Allday, 2003; O'Nions et al., 2006 and our unpublished data) .
Discussion
Using a genetic approach, we have shown that two EBV nuclear oncoproteins-EBNA3A and EBNA3C-that both play a critical role in the immortalization of B cells EBNA3A and EBNA3C repress Bim expression E Anderton et al by EBV, cooperate to enhance the survival of p53-null BL cells challenged with cytotoxic drugs. We have described experiments using the microtubule disrupting drug nocodazole, the DNA cross-linking agent cisplatin and the cyclin-dependent kinase inhibitor roscovitine, suggesting that all these agents activate a common p53-independent pathway targeted by EBNA3A plus EB-NA3C. This phenotype is not apparent in Bim-negative BL2 cells and correlates with EBNA3A and EBNA3C cooperating to repress the expression of Bim. The possible role of Bim as a mediator of cisplatin-induced apoptosis is surprising, since p53 status rather than Bim status is generally considered to be the more important in responses to genotoxins. Although our results are consistent with Bim influencing responses to DNAdamaging agents like cisplatin in BL cells, at this stage we cannot formally exclude the possibility that there may also be some EBNA3A/3C-associated, Bim-and EBNA3A and EBNA3C repress Bim expression E Anderton et al p53-independent pathway that is activated by cisplatin but has yet to be characterized. Most of the data presented here suggest that EBV (via the action of EBNA3A and EBNA3C) regulates Bim expression at the level of transcription; however, we cannot formally exclude other layers of regulation (for example, RNA or protein stability) playing a minor role. Neither can we be sure that EBNA3A plus EBNA3C are sufficient to repress Bim expression in B cells. Although deleting EBNA3A or EBNA3C in BL31 cells resulted in an increase in EBNA2, because completely deleting EBNA2 has no significant effect on Bim expression (or responses to cytotoxic drugs), we do not consider that there is any compelling evidence linking the raised EBNA2 levels to the increased Bim expression or reduced survival seen in the EBNA3A and EBNA3C-KO lines. Details of the mechanism by which EBNA3A and EBNA3C work in combination to inhibit Bim expression remain to be established. However, since they both repress transcription when targeted to DNA and interact with complexes that include co-repressors and silencers of transcription, it is tempting to speculate that EBNAs 3A and 3C form part of a multi-protein repression complex that inhibits transcription from BIM. The BIM locus is complex and the regulatory elements probably extend over 10-12 kb and may include intronic sequences. Our preliminary analysis suggests that EBNA3A and EBNA3C have effects on a 785 bp promoter fragment (described in Essafi et al., 2005) that are consistent with the results presented here; however, the effects are rather modest and do not fully explain the expression phenotype we see associated with the gene in a chromosomal context (our unpublished results). Nevertheless, whatever the mechanism, the large reduction in the amount of Bim produced by latent EBV will have a profound effect on the physiology and survival potential of infected B cells.
Bim is a major regulator of life-and-death decisions during lymphopoiesis, and it has been suggested that it is the principal BH3-only protein expressed in IgMbearing mature B cells (reviewed Strasser, 2005) . Bim is thought to be a direct initiator of apoptosis that binds all the prosurvival Bcl-2-family members to inactivate them, but may also bind and activate the proapoptotic proteins Bax and Bak (Strasser, 2005) . BIMÀ/À mice accumulate excess lymphoid and myeloid cells and can develop an SLE-like autoimmune disease (Bouillet et al., 1999) . Loss of Bim accelerates B-lymphomagenesis induced by an Em-MYC transgene and even loss of a single allele of BIM accelerates lymphomagenesis significantly (Egle et al., 2004) . This indicates BIM is a haploinsufficient tumour-suppressor and that the level of Bim is a critical rate-limiting factor in B cell survival. Consistent with this, two recent studies have revealed deletions of the BIM locus in up to 40% of human mantle cell lymphomas (Tagawa et al., 2005; MestreEscorihuela et al., 2007) . Moreover, the level of Bim is an important determinant of sensitivity to anti-cancer chemotherapeutic agents (including spindle poisons, such as nocodazole and taxol) in a variety of cell types (Bouillet et al., 1999; Tan et al., 2005) . It is clear that BIM is a uniquely important tumour-suppressor in B-lymphocytes and modulation of its expression by EBNA3A and EBNA3C is therefore likely to be a major contributory factor in the development of any EBVassociated B-lymphoma. It may be particularly significant that regulation of BIM plays a critical role in the pathogenesis of lymphomas-such as BL-that involve deregulation of the oncoprotein Myc. . Protein extracts from BL2 and BL31 cells, and from cells infected with an EBNA2-knockout virus (E2KO), were separated by SDS-PAGE (12.5%) and western immunoblotted with antibodies against Bim and g-tubulin (a control for equal loading). Bim expression is inhibited in the presence of latent EBV in BL31, but Bim is undetectable in BL2 cells. (b) BL2 cells converted by infection with recombinant EBVs express the expected EBV latency-associated proteins. Protein extracts were prepared from BL2 cells infected with wild-type (WT) EBV, EBNA3A-, EBNA3B-and EBNA3C-KO and revertant (Rev) viruses. Proteins were resolved by SDS-PAGE and western immunoblotted with antibodies against EBV latent proteins and g-tubulin (a control for equal loading). An extract from the EBV-negative parental BL2 cell line was used as a negative control, and an extract from an LCL was used as a positive control. (c) In the absence of Bim, EBNA3A and EBNA3C provide no survival advantage. BL2 cells and their EBV-positive counterparts were treated with nocodazole (50 ng/ml) for 72 h. The percentage of viable cells surviving after treatment was determined. The survival of BL31 and BL31 infected with wild-type (WT) EBV under similar conditions is shown for comparison. In every case, the mean of three independent experiments was plotted with error bars to indicate standard deviations. (d) Proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) induced by nocodazole in BL2 cells is not inhibited by latent EBV. Cells were treated with nocodazole (noc) and at the times indicated, samples were taken and protein extracts prepared. Proteins were resolved by SDS-PAGE (7.5%) and western immunoblotted with antibodies against PARP and g-tubulin. Full-length (113 kDa) PARP and the 89 kDa product of caspase-mediated cleavage are both indicated by arrows. (e) The proapoptotic BH3-only protein Noxa is induced by nocodazole in BL2 cells and an LCL. BL2, BL2 infected with the wild-type (WT) virus and LCL-BF were treated with nocodazole (noc, 50 ng/ml) for 72 h and at the times indicated, samples were taken and protein extracts prepared. Proteins were resolved by SDS-PAGE (15%) and western immunoblotted with antibodies against Noxa and g-tubulin. The status of p53 genes in BL2 was reported previously (Lindstrom et al., 2001 ) and the complete genomic DNA sequence of p53 in BL31, Sal and Oku was determined. In Em-MYC mice that are BIM þ / þ , B-lymphomas arise stochastically over more than a year and in most tumours the p19 ARF /p53 apoptotic pathway has been inactivated (usually by mutation of p53 or p19 ARF ). However, in the BimÀ/À Em-MYC mice, tumours arise much more rapidly and the selection pressure for functional inactivation of the p53 apoptotic pathway appears to be completely removed (Egle et al., 2004) . Extending this MYC-lymphoma model to human lymphomagenesis, Lowe and colleagues investigated the relationship between MYC, p53 and Bim in BL (Hemann et al., 2005) . Deregulated MYC is a hallmark of all BL and this deregulation occurs through reciprocal translocations that juxtapose MYC with an immunoglobulin promoter/enhancer, leading to constitutive overexpression of Myc in mature B cells. Point mutations are sometimes found in the translocated MYC alleles, often clustering in conserved box 1. Two commonly observed mutants of Myc that are found in BL-P57S and T58A-retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis because they fail to induce the expression of Bim seen when wild-type MYC is overexpressed (Hemann et al., 2005) . Since tumours carrying codon 57/58 mutations of MYC often retain a functional p53 pathway, but wild-type MYC is generally accompanied by genetic lesions in the p53 pathway, this has led to the proposal that MYC-induced apoptosis involves a threshold phenomenon in which inactivation of any one of several MYC effectors (for example, p53, p14/p19 ARF , Bim) can cause apoptosis-firing to drop below a critical threshold and allow cell proliferation (Dang et al., 2005; Hemann et al., 2005 ; summarized in Figure 6a ).
The results we have presented here suggest that EBV, through the action of EBNA3A and EBNA3C, can be operationally equivalent to MYC 57/58 mutants since in infected cells induction of Bim by Myc would be inhibited and Bim levels kept very low. An important prediction based on this observation is that expression of EBNA3A and EBNA3C will create a B cell environment in which translocation of a wild-type MYC can be tolerated-even if subsequently EBNA3A and EBNA3C are downregulated to produce the restricted latency-I pattern of viral gene expression commonly found in BL. As a consequence, EBV infection will increase the frequency with which BL may become established because not only will deregulated MYC be tolerated, but also the rate of translocations and somatic mutations may be increased (Epeldegui et al., 2007) . A further prediction is that the subset of BL retaining expression of EBNAs 3A and 3C (Kelly et al., 2005 (Kelly et al., , 2006 should be able to tolerate both wild-type Myc and wild-type p53. We performed DNA sequence analysis on the p53 and MYC genes of Sal-BL and Oku-BL-two newly established BL cell lines that express all the EBNA3 proteins-and revealed that this was indeed the case (Table 1) .
To summarize: the use of novel recombinant 'KO' and 'revertant' viruses has allowed us to unequivocally demonstrate that Bim is a major target for EBV and requires two cooperating EBNAs to inhibit its expression. For the first time, this shows EBNA3A and EBNA3C functionally cooperate to regulate a cellular , through the action of EBNA3A and EBNA3C, is operationally equivalent to Myc mutants; therefore, a wild-type MYC translocation can be tolerated and can induce lymphomagenesis despite wild-type ARF/p53. This schematic was adapted from (Dang et al., 2005) . (b) The balance between EBNA3A plus EBNA3C and EBNA2 is probably necessary to prevent Bim-induced apoptosis in EBV-associated B-cell transformation and persistence. EBNA2 directly transactivates MYC, and therefore will indirectly induce Bim expression, reset the apoptotic threshold and sensitize cells to Bim-mediated apoptosis. If EBNA3A and EBNA3C are expressed they will counteract this-facilitating cell survival.
gene and demonstrates that in the context of latent infection they play a major role in cell survival. Since newly infected B cells will express the EBV transactivator EBNA2, which constitutively activates the expression of Myc (Kaiser et al., 1999) and therefore, indirectly, Bim (Hemann et al., 2005) , EBNA3A and EBNA3C may have evolved this activity to prevent EBNA2-induced, Bim-mediated apoptosis in infected B cells (Figure 6b) . Furthermore, since preventing the activation of Bim by a deregulated MYC can be a critical event in the development of BL, then the repression of Bim mRNA levels by EBNA3A and 3C is likely to make a significant contribution to the development of at least some eBL. This may explain the selection pressure that retains EBNA3 expression in a small but significant subset of BL (Kelly et al., 2005 (Kelly et al., , 2006 .
Materials and methods
Generation of EBNA3 gene-deleted and revertant EBV and infection of BL cells
Individual EBNA3 genes were deleted from the EBV genome by RecA-based homologous recombination between the B95.8 EBV-BAC (p2089, Delecluse et al., 1998) and a shuttle plasmid containing a fragment of the EBV genome, as described previously (White et al., 2003;  Figure 1a and Supplementary Figure 1b ). The deleted gene was then restored in each case to generate three revertant BACs. A full description of the recombination and screening process, along with the methods used to generate infectious virus and infect EBV-negative BL cells, can be found in Supplementary Information.
Cell culture EBV-negative BL cell lines BL2 and BL31 are described elsewhere (Calender et al., 1987) . BL31 and BL2 cells infected with a recombinant EBNA2-KO virus (BL31 þ E2KO and BL2 þ E2KO) were a kind gift from Kelly et al. (2005) . All BL lines were cultured in RPMI-1640 medium (Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum, penicillinstreptomycin, glutamine, 1 mM sodium pyruvate (Sigma, Poole, UK) and 50 mM a-thioglycerol (Sigma). Hygromycin B (Roche, Burgess Hill, UK) was added at a concentration of 100 mg/ml to all BLs containing recombinant hygromycin-resistant EBV. The isolation of primary B cells and their stimulation with CD40L and IL4, or their infection with EBV to produce LCLs, has been described previously (O'Nions and Allday, 2003) . For routine passage, cells were split 1:3 every 3-4 days. For experiments, all cells were re-suspended in fresh medium at a density of 3 Â 10
